Quest Partners LLC Has $241,000 Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)

Quest Partners LLC boosted its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML) by 145.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 9,381 shares of the company’s stock after buying an additional 5,559 shares during the period. Quest Partners LLC’s holdings in Tourmaline Bio were worth $241,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TRML. China Universal Asset Management Co. Ltd. increased its holdings in shares of Tourmaline Bio by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock valued at $127,000 after purchasing an additional 1,920 shares during the period. Janus Henderson Group PLC bought a new stake in Tourmaline Bio in the first quarter worth $266,000. California State Teachers Retirement System acquired a new position in Tourmaline Bio during the first quarter worth $334,000. Rhumbline Advisers raised its holdings in Tourmaline Bio by 28,554.3% during the second quarter. Rhumbline Advisers now owns 33,239 shares of the company’s stock valued at $427,000 after buying an additional 33,123 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Tourmaline Bio in the second quarter worth about $433,000. 91.89% of the stock is owned by hedge funds and other institutional investors.

Tourmaline Bio Stock Performance

NASDAQ TRML opened at $23.82 on Wednesday. The stock has a 50-day simple moving average of $25.88 and a 200 day simple moving average of $18.87. Tourmaline Bio, Inc. has a twelve month low of $12.12 and a twelve month high of $48.31. The stock has a market capitalization of $610.82 million, a PE ratio of -8.45 and a beta of 2.36.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.06. As a group, equities research analysts forecast that Tourmaline Bio, Inc. will post -3.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TRML has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised Tourmaline Bio to a “strong-buy” rating in a research note on Tuesday, October 15th. HC Wainwright boosted their price objective on shares of Tourmaline Bio from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Tourmaline Bio has an average rating of “Buy” and an average price target of $65.00.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.